ABL1 and acute lymphoblastic leukemia: In addition, VS-4718 (50 mg/kg) had a synergistic effect in combination with dasatinib, (a tyrosine kinase inhibitor targeting Src and BCR/ABL - breakpoint cluster region-Abelson murine leukemia kinase - widely used in frontline treatment of Ph+ B-ALL) in affecting cell survival, adhesion, and inhibition of downstream targets of FAK (47).